Help slow Parkinson disease progression
- Trial ID
- NCT04888364
- Official Title
- Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
- Goal
- Help slow Parkinson disease progression
- Status
- RECRUITING
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Study Type
- OBSERVATIONAL
- Enrollment
- 30000 participants
- Conditions
- Parkinson Disease
Plain-Language Summary
Goal: Gather long-term clinical, genetic, imaging, and biological data across France to better understand how Parkinson's and related parkinsonian disorders begin, progress, and vary between people, and to identify early risk markers. Approach: People join an observational cohort with regular clinical exams and optional biosamples like blood and skin biopsy plus imaging when available, so researchers can link symptoms to biological and genetic clues; no experimental drug is given and usual treatments such as levodopa are continued as needed. Eligibility: Open to anyone age 10 and up who is covered by French social security and who has Parkinson's, another parkinsonian syndrome, or is at increased risk (for example a relative of a patient, a known PD gene carrier, or someone with idiopathic REM sleep behavior disorder), provided they can give informed consent and are not under legal protection.
Locations
- Centre 01 Paris, Paris, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. Goal: Gather long-term clinical, genetic, imaging, and biological data across France to better understand how Parkinson's and related parkinsonian disorders begin, progress, and vary between people, and to identify early risk markers. Approach: People join an observational cohort with regular clinical exams and optional biosamples like blood and skin biopsy plus imaging when available, so researchers can link symptoms to biological and genetic clues; no experimental drug is given and usual treatments such as levodopa are continued as needed. Eligibility: Open to anyone age 10 and up who is covered by French social security and who has Parkinson's, another parkinsonian syndrome, or is at increased risk (for example a relative of a patient, a known PD gene carrier, or someone with idiopathic REM sleep behavior disorder), provided they can give informed consent and are not under legal protection.
- Who can participate?
- Participants must be at least 10 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years.